Abstract Modern association studies often involve a large number of markers and hence may encounter the problem of testing multiple hypotheses. Traditional procedures are usually over-conservative and with low power to detect mild genetic effects. From the design perspective, we propose a two-stage selection procedure to address this concern. Our main principle is to reduce the total number of tests by removing clearly unassociated markers in the first-stage test. Next, conditional on the findings of the first stage, which uses a less stringent nominal level, a more conservative test is conducted in the second stage using the augmented data and the data from the first stage. Previous studies have suggested using independent samples to avoid inflated errors. However, we found that, after accounting for the dependence between these two samples, the true discovery rate increases substantially. In addition, the cost of genotyping can be greatly reduced via this approach. Results from a study of hypertriglyceridemia and simulations suggest the two-stage method has a higher overall true positive rate (TPR) with a controlled overall false positive rate (FPR) when compared with singlestage approaches. We also report the analytical form of its overall FPR, which may be useful in guiding study design to achieve a high TPR while retaining the desired FPR.
Introduction
Genetic association analysis has been used widely in the search for genes contributing to complex diseases. One common study design is to collect genomic data from affected and unaffected unrelated individuals, and contrast their genetic features at the level of gene expression (e.g., Hedenfalk et al. 2001; Haga et al. 2002; Ozaki et al. 2002) or marker distribution frequencies (e.g., Risch and Merikangas 1996; Collins et al. 1999) . Such studies tend to encounter the problem of multiple testing due to the use of densely spaced markers (Ohashi and Tokunaga 2001) . In that case, the Bonferroni procedure, which aims at preventing the occurrence of a single false positive, is frequently adopted. However, the traditional Bonferroni procedure is known to be an over-conservative test because its critical value becomes extremely large when many hypotheses are examined simultaneously.
Several approaches have been proposed with which to pursue higher power in a multiple-testing setting. One direction is to modify the testing procedures, and focus on constructing more powerful tests (see Dudoit et al. 2003 for review). Improved procedures have been obtained either by considering measures different from overall type I error rate, such as false discovery rate (FDR; e.g., Benjamini and Hochberg 1995; Storey and Tibshirani 2003; Tsai et al. 2003) , or by empirically obtaining the significance threshold of multiple tests (e.g., Ge et al. 2003; Becker and Knapp 2004) . Another direction adopts the design point of view, and accounts for both power and cost. Our proposed approach is motivated by the design perspective.
Given that the cost of a genetic study is largely determined by the number of individuals recruited and the number of markers genotyped, sequential designs to enhance study efficiency are becoming increasingly popular (e.g., Bo¨ddeker and Ziegler 2001; Saito and Kamatani 2002; van den Oord and Sullivan 2003a, b; Thomas et al. 2004; Hirschhorn and Daly 2005) . Either samples or marker density or both may be increased sequentially. Such strategies have also been proposed to deal with low power due to the Bonferroni correction. For example, for array experiments, Miller et al. (2001) suggested first selecting a smaller set of microarray sample and proceeding to the second stage of tests with another data set using only genes found significant in the first stage. Later, Allison and Coffey (2002) pointed out that this two-stage method can be even more conservative if the two significance levels are not chosen carefully. Several other papers have proposed different two-stage methods from different perspectives. Hoh et al. (2000) and Ott and Hoh (2001) proposed first selecting a smaller subset of single nucleotide polymorphisms (SNPs) and then using them in the modeling stage to reduce the number of coefficients to be estimated. Elston et al. (1996) and Guo and Elston (2000) proposed genotyping at two different spacings to save cost. Several authors (see, for instance, Saito and Kamatani 2002; Satagopan and Elston 2003; van den Oord and Sullivan 2003a, b) advocated the use of two-stage (or multi-stage) procedures that inflate the probability of false positives in the first stage, and control this probability in later stages. Others have focused on genotyping cost, allocation of sample sizes, and selection of significance levels in two-stage designs. Satagopan et al. (2002 Satagopan et al. ( , 2004 considered a two-stage design under the constraint of a fixed total number of genotypings. Saito and Kamatani (2002) performed extensive simulation studies based on various combinations of type I error in the first stage, sample sizes at two stages, and genotype relative risks, in the search for an optimal design. Their two tests conducted at two stages use different, and hence independent, data. Thomas et al. (2004) used the likelihood approach to select tagging SNPs in the second stage using a larger sample that combines previous data.
Here we introduce a design for a two-stage procedure for multiple testing that includes data from the first stage. We conduct a formal test in the second stage, conditional on the findings of the first, with both the original and the augmented data. In the first stage, the objective is to eliminate those markers that are very unlikely to be associated with the disease of interest among the total number (M) of markers. A large significance level is used, and markers with ''large'' P values are excluded. In other words, at this stage we intend to include as many true positives as possible by tolerating a larger-than-usual amount of false positives. This follows the same idea as that proposed by van den Oord and Sullivan (2003a, b) , i.e., relaxing the false positive probability in the first stage. After obtaining a smaller and more promising set of markers, we conduct statistical tests with a stringently controlled overall type I error using a combination of data from the first-stage sample and the newly genotyped data. van den Oord and Sullivan (2003a) and others (Miller et al. 2001; Saito and Kamatani 2002; Satagopan et al. 2002) considered only new data in their secondstage test to avoid complexity in test statistics due to interdependence between the first and second samples. As argued by van den Oord and Sullivan (2003a) , inclusion of first-stage data may elevate false positive discoveries, but can reduce the genotyping burden. Here, we recommend incorporating both samples and we show that the increase in false discovery can be reduced by use of a larger sample size and a more stringent significance level. A test with combined data will save on overall genotyping costs, as long as the dependence and its effect can be handled carefully. This point is similar to that mentioned in Satagopan and Elston (2003) although they did not pursue it further. The proposed procedure is designed to enlarge the power of each test in the first stage and reduce the type I error in the second stage. Overall, the procedure is more powerful at a controlled false positive rate (FPR), and avoids waste of resources in genotyping markers with no association.
In this paper, we use the term true positive rate (TPR) for the probability of rejection of truly associated markers, and FPR for the probability of rejection of non-associated markers. The FPR can be considered as a measure of the overall type I error rate. However, we use TPR and FPR when referring to the overall performance of M multiple tests, and retain type I and II errors when considering each single test. In the following section, we explain the rationale of the design, discuss its implementation, and derive theoretical success and failure rates. More technical details can be found in Appendices 1 and 2. Simulation studies and a real example are then considered. The performance of the method, in terms of TPR and cost saving, is evaluated and compared with other Bonferroni type procedures.
Materials and methods

Two-stage selection procedure
In the first stage, we consider a large significance level, a 1 , for each test to ensure that even markers with mild effects will be detected. The aim of obtaining a large TPR at this stage will then be guaranteed. For instance, in population-based case-control studies, a chi-square test for contingency tables or z-test for comparing two proportions can be considered. Taking a 1 =0.05 results in a large power in the first stage for M SNPs (or markers), each with N 1 allele data value. For SNPs, N 1 is the number of total allele counts from the case group and N 1 /2 is the number of cases. The resulting significant R markers will proceed to the second testing procedure. In this stage, the sample size for each of the significant R markers will be enlarged by the N 2 allele data for each marker. That is, only the R markers of the additional individuals will be genotyped. Therefore, the total number of genotypings is MN 1 in the first stage and RN 2 in the second. The total cost (MN 1 +RN 2 ) is much smaller than that (MN 1 +MN 2 ) in a single-stage design. When testing the association of the R markers in the second stage, we adopt a smaller significance level, a 2 , for each test such that the overall FPR decreases. Some power may be sacrificed but the inclusion of the additional sample will compensate for the loss. The final significant X markers can now be used for further studies such as fine mapping.
In the first stage, our proposal categorizes M markers into two groups: those with large P values (i.e., obviously removable) and the rest (possibly associated). Any induced error due to loose separation can be corrected in the second stage. For instance, one may apply the traditional stringent Bonferroni correction to test the R markers at this stage or use Benjamini and Hochberg's procedure (1995) to control the FDR. This combination ensures a high overall success rate (the TPR) and a low error probability (the FPR).
Notation and implementation
Among the total M markers, let w be the fraction of markers that are truly non-associated with the disease, and M(1Àw) be the number of associated markers that we want to identify. The proportion w is usually close to 1 in a large-scale association study (Ozaki et al. 2002) . Let N 1 be the sample size of allele data considered in the first stage. Without loss of generality, here we assume the sample size of the case and of the control group to be the same, with N 1 allele data from cases and N 1 from controls. For the purposes of illustration, we take individual biallelic markers as the basic unit for association testing. The results can be generalized to other association tests at haplotypic or genotypic level.
For each marker, let a 1 =0.05 be the significance level in the first stage, and 1Àb 1 the corresponding power. Suppose that after M tests in the first stage, R (R=R 0 +R a ) markers result in significance, where R 0 are from the original Mw markers of no association and R a from the M(1Àw) markers with association. In the second stage, we increase the sample size by N 2 for each case and control group. Next, we genotype only the R markers of the additional N 2 subjects and perform a second test on these markers of N 1 +N 2 individuals based on significance level a 2 where a 2 <a 1 . In terms of genotyping, as suggested by Satagopan et al. (2002) , the total number of gene evaluations up to this point is MN 1 +RN 2 . The final total of significant markers, after the second stage, is denoted as X (X=X 0 +X a , where X 0 results from R 0 and X a from R a ).
True positive and false positive rates and numbers An intuitive measure for a successful testing procedure is the TPR, which can be considered as the overall power.
The TPR can be denoted as a product of two conditional probabilities, U 1 and U 2 (see Appendix 1), for success in detection at each stage, respectively. These two conditional probabilities depend on the testing procedures and significance levels employed. In the same manner, we express the overall FPR as a product of the two conditional probabilities Q 1 and Q 2 for incorrect rejection at each stage. Their values depend on both a 1 and a 2 . The a 1 can be fixed at a large value, say 0.05, to ensure a high probability of true significance in the first stage. The a 2 , however, will be made smaller to control the overall false positive results. For instance, we recommend a 1 /R for a 2 , where R is determined after the test in the first stage is complete. From Appendix 1, expectations of TPR and FPR can be approximated by (1Àb 2 ) and a 2 , respectively, under conditions discussed later.
The sample sizes N 1 and N 1 +N 2 also affect FPR. Based on the results in Appendix 1, by setting the proportion of N 1 to N 1 +N 2 larger than ðz 1Àa 1 =2 =z 1Àa 2 =2 Þ 2 , the overall FPR will be controlled at the level of a 2 . A planned design with properly chosen significance levels (a 1 >a 2 ) and sample sizes (N 1 >N 2 ) will ensure a high overall TPR. Alternatively, the approximated TPR and FPR can be fixed together to determine the sample sizes.
Given M and w, R 0 is binomially distributed with the number of trials Mw and probability Q 1 , assuming independence between M tests. Similarly, the number of true positives, R a , is binomially distributed with size M(1Àw) and probability U 1 . When the significance level of the first stage is fixed at a 1 for each test, the overall Q 1 becomes a 1 , and U 1 is equivalent to (1Àb 1 ). Similarly, when a 1 and a 2 are fixed, the conditional probability of incorrect rejection (Q 2 ) can be approximated by 1/ [E(R 0 )+E(R a )], and U 2 by the expected value, E(1Àb 2 )/ (1Àb 1 ) (details in Appendix 1), where the expectations, E(R 0 )=MwQ 1 and E(R a )=M(1Àw)U 1 , are taken with respect to the binomial distributions, respectively, at given values of M, w, Q 1 , and U 1 .
Therefore, the expected number of correctly identified markers (true positives), E(X a ), can be approximated by M(1Àw) · E(1Àb 2 ) where E(X a )=R a U 2 if R a and U 2 are given. Similarly, following the argument above, the number of false positives, X 0 , is binomially distributed as Bin(R 0 ,Q 2 ). The probabilities of obtaining zero or one non-associated marker can be estimated. For instance, the sum is approximately 0.92 when M =500, w =0.95, and a 1 =0.05, which implies a less-than-one false alarm.
Results
Example: association with hypertriglyceridemia
The two-stage procedure was applied to a small data set containing only 15 SNPs as markers. These markers locate in the exons and introns of the four genes, lipoprotein lipase (LPL), apolipoprotein A1 (APOA1), apolipoprotein C3 (APOC3), and apolipoprotein A5 (APOA5). There are two, four, four, and five markers contained in each gene, respectively. The last five markers on the APOA5 gene have been previously tested for association with hypertriglyceridemia (Kao et al. 2003) . The latter study revealed that, when all samples (290 hypertriglyceridemia and 303 controls) are considered, three markers (c.553G > T, c.1259T > C, and IVS3 + 476G > A) are statistically significantly associated with hypertriglyceridemia after Bonferroni's correction.
For the purposes of illustration, we selected 198 individuals randomly from each case and control group in the first stage, and conduct 15 tests each with a 1 =0.05. The significant markers (R markers) then enter the next stage with the data increased by adding the genotypes on each of the R markers of the remaining 197 (197=593À198À198) individuals. Each marker is tested with the significance level a 2 =0.05/R. The resulting significant markers are considered as showing evidence of association. This procedure is replicated 100 times to assess its performance and to account for sampling variation.
In each replication, we also compute the number of total genotypings, and divide it by 15 to derive the corresponding sample size KðK Table 1 lists the percentages of significance of each marker over 100 replications. For the purposes of comparison, we consider the results from Bonferroni correction with all data as the hypothetical standard. In other words, markers numbered 7, 9, 10, 12, 14, and 15 with a larger difference in minor allele frequency are considered associated with hypertriglyceridemia. When markers have a strong effect (numbers 12, 14, and 15 in APOA5), it is easy to distinguish between case and control groups. All methods were shown to be consistent. For markers of lesser strength (numbers 7, 9, and 10 in APOC3), the two-stage method reaches the same conclusion as the Bonferroni procedure with all data [B(all)]. However, the average number of genotypings for the two-stage method is only 7,313.09 (7,313.09= 15·396+6.97·197 where 6.97 is the average R), i.e., 82% [82%=7,313.09 / (15 · 593)] of the number required under B(all).
When compared with Bonferroni procedure with the same number of genotypings [B(K)], the two-stage method correctly identifyies the association with a much higher percentage ( ‡94%), while B(K) performs poorly under the same number of genotypings.
In another analysis with N 1 =298 (149 cases) and N 2 =295, the two-stage selection procedure still identifies the same signals as Bonferroni's method (results not shown), and the average relative cost in genotypings is only 72%.
Simulation studies
In this section, we describe simulation studies to evaluate the success and error rates of the two-stage selection method. The final numbers of truly significant markers X a and TPR X a /(M(1Àw)) are used to assess success, while the numbers of falsely significant markers X 0 and FPR X 0 /(Mw) are adopted to quantify error. The results are compared with those of single-stage methods such as Bonferroni's procedures. As stated in Reich et al. (2003) , the minimal allele frequency of most discovered SNPs is greater than 10%. Therefore, we assume in the following that the allele frequencies range between 10% and 90%. That is, the allele frequencies p c and p n for the case and control groups, and their weighted average " p all fall within this interval (10-90%). The range of their absolute difference, d ðd ¼ jp c À p n jÞ, can consequently be derived (Appendix 2). The ranges of the two quantities are shown in Fig. 1 . If the genotyping can be made almost free of error so that the allele frequency takes values from 0 to 1, then the range of the two quantities would be larger, as indicated by the dashed lines in Fig. 1 . We have fixed M at 500 (Table 2) or 500,000 (Table 3) , w=0.95, and N 1 =2,000. Numbers of allele counts for Mw non-associated SNPs were simulated under the null H 0 :d=0 with given " p, while other M(1Àw) associated SNPs were with a given d>0. We then tested each marker with a 1 =0.05. If any significance was found, an additional sample of size N 2 =1,000 would be generated and tested with a 2 =0.05/R. 
TPR and FPR
The average TPR for the two-stage method is substantially greater than that of either of the two Bonferroni procedures. Even when the difference in frequency is small (d<0.05), the two-stage method is still superior. However, when the difference is extremely small (d=0.01), all methods fail to perform satisfactorily. In fact, the required sample size in this case would be larger than 15,000. That is, more subjects are needed to achieve a reasonable power. The second factor of TPR is the average frequency " p. When " p approaches 0.5, all TPRs decrease, but the twostage method still outperforms the rest. Between the two Bonferroni procedures, the one with the greater sample size performs better than the other. It should be kept in mind, however, that the cost for B(all) method is larger than others and it requires more laboratory work. When looking at FPR and FDR, the two-stage method is not as good as the other two. However, these numbers are indeed small. For example, the FPR of 0.158·10 À2 (Table 2) implies less-than-one false alarm. The FPRs for both Bonferroni procedures are small, indicating a very slim chance of identifying an unassociated marker, which is as conservative as we had expected. The TPR and FPR from simulation studies also match the theoretical values quite well in both cases (M =500 or 500,000), indicating that the equations derived in Appendix 1 are good approximations. ). This finding is consistent with the theoretical derivations in the Methods section. Figure 3 displays TPR, FPR, and FDR with respect to various values of M, and different settings of N 1 and N 2 . First, it can be seen that the patterns do not change even if M is as large as 500,000. Second, in Fig. 3a and d, the TPR of the two-stage method with dependent samples outperforms both the two-stage method with independent samples and Bonferroni's method. Third, Fig. 3b,c,e,f show that the errors, in terms of FPR and FDR, of the two-stage method with dependent samples are larger than those seen with the other two methods; however, the difference is very small. We conclude that when correct detection is of concern, the test with dependent samples will be better. When reducing the possibility of false detection is the focus, the test with independent samples should be adopted. Table 3 The FPR and TPR based on simulations (numbers in parentheses are theoretical values) for the proposed two-stage method and two Bonferroni procedures. The total number of markers is assumed to be M =500,000 while the increase in TPR can be as high as 39% when " p ¼ 0:15 and d=0.05. In fact, the increase in TPR is quite dramatic and can be larger than 40%, particularly when d £ 0.05. Meanwhile, the magnitude of FPR is still less than 0.001. A similar pattern can be found when comparing B(all) with the two-stage method. The increase in TPR is greater than 30% for d £ 0.05 (except when d=0.05 and " p ¼ 0:15), and the two-stage procedure saves about 30% in costs compared with B(all).
Discussion
In this paper, we have proposed a two-stage method for multiple hypotheses testing to avoid multiplicity effects. The selection procedure aims at retrieving markers with little or mild association, incorporating two types of errors simultaneously, thus saving on overall costs in genotyping. We also derived the theoretical boundaries of TPR, FPR, and expected counts of true and false significance. When compared with two traditional Bonferroni procedures, the two-stage method outperforms. However, when d is extremely small, none of the methods tested provides satisfactory results unless a study of a much larger size can be conducted.
Although we have used SNPs as an illustration throughout this paper, the method is not restricted to this type of data. If genotypes are considered, say three genotypes per locus, chi-square tests can be conducted based on 3·2 contingency tables, and the two-stage method can be similarly implemented. When pedigree data are of interest, the unit of observation becomes the vector for each family per locus. The test statistic can be constructed based on multivariate data and the twostage procedure can be applied. The method can also be used in microarray data provided the number of subjects is not too small. In any case, the scheme does not change with the statistics used.
Through use of the two-stage design, the original power of a test statistic is always increased. This design guarantees a greater overall power than that achievable in a single stage of testing. If dependence among data exists, tests incorporating such relationships may be considered (Benjamini and Yekutieli 2001; Dale 2004) . When a multi-stage approach is employed (van den Oord and Sullivan 2003a; Hirschhorn and Daly 2005) , this procedure can be generalized with care for the derivation of TPR and FPR. It is worth noting that pooling data from all previous stages will be more powerful, but the tests must be carefully conditioned on results from previous stages to handle dependence, as illustrated here.
Another issue concerns the relative magnitude of sample sizes. Once a statistic is chosen to test the significance between case and control groups, the standard formula for the sample size can be applied based on given a 1 and a 2 . The magnitudes of N 1 and N 2 are then determined. Our findings also assure that, since power is the primary interest in the first stage, a larger N 1 will guarantee a greater overall TPR. If one is more concerned about error rates, then a larger N 2 should be considered (van den Oord and Sullivan 2003a) . Further studies on an optimal choice of the relative magnitudes of N 1 and N 2 , and an investigation into constraints on haplotype size (or the number of SNPs) will be considered in a future manuscript.
Appendix 1
TPR is defined as TPR Prðreject nulljtruly associatedÞ ¼ Prðsignificant in first and second stagej truly associatedÞ ¼ Prðsignificant in firstjtruly associatedÞ Â Prðsignigicant in secondjsignificant in first, truly associatedÞ
Similarly, by the same argument for conditional probability, the overall FPR is FPR Prðsignificantjno associationÞ ¼ Prðsignificant in firstjno associationÞ
Define T(X) as the test statistic used in the first stage where X denotes the data from MN 1 genotypings, and T(X*) for the second stage where X* contains the information based on the R (N 1 +N 2 ) genotypings. The test statistic can be the difference in allele frequency between the case and control groups, or a chi-square statistic derived from contingency tables. These two statistics are correlated because partial data are used in both X and X*. Without loss of generality, we assume here that both statistics converge asymptotically to normality, providing N 1 is large, and that the allele frequencies obtained from N 1 and N 1 +N 2 are roughly equal. Let q denote the correlation between T(X) and T(X*), the overall FPR at a 1 and a 2 is then:
PrðT ðXÞ ! a; T ðX Ã Þ ! bÞ
where P ¼ 11 and P À1=2 ¼ s t t s whose elements depend on q. Applying their asymptotic normality with zero mean vector and the covariance matrix P , the above becomes
where a ¼ z 1Àa 1 =2 and b ¼ z 1Àa 2 =2 ¼ z 1Àa 1 =2R are the percentiles of standard normal, and Z 1 and Z 2 are independent standard normal distributions. This FPR will be bounded closely from above by PrðZ 2 ! t Á a þ s Á bÞ if q is large. This boundary is determined by a 1 , a 2 , R, and q, and is smaller than 0.001 when R ‡10; while a quick guess for R would be M a 1 . If q=0, this boundary becomes Pr(Z 2 ‡ b), which is simply a 2 .
To investigate the effect of sample size, note that T(X) is close to ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi To derive the expected number of success and error counts, it suffices to calculate the path probability Q 2 in the second stage. Conditional on a 2 =a 1 /R, its upper bound becomes a 2 /a 1 , and is approximately 1/ [E(R 0 )+E(R a )]. Similarly, the conditional probability U 2 , at fixed a 1 and a 2 , is approximately (1Àb 2 )/(1Àb 1 ).
Appendix 2
Let p c and p n represent the allele frequencies for the case and control groups, respectively, and d their absolute difference. Let " p be their average, weighted by corresponding sample sizes N c and N n . Following the assumption that the allele frequency ranges from 10% to 90%, it can be derived that 90% ! maxðp c ; p n Þ ¼ " p þ d=2 ! 10%; 90% ! minðp c ; p n Þ ¼ " p À d=2 ! 10%; 0:1 " p 0:9; À0:8 p c À p n 0:8; 0 d minð0:8; 2" p À 20%Þ: 8 > > > > < > > > > : Therefore, the relationship between " p and d can be formulated. In the general form, when p 0 stands for the detectable minimal allele frequency, the above equation becomes 8" p 2 ðp 0 ; 0:5Þ; d 2 ð0; 2" p À 2 Â p 0 Þ; 8" p 2 ð0:5; 1 À p 0 Þ; d 2 ð0; 2 Â ð1 À p 0 Þ À 2" pÞ:
